Meitheal Pharmaceuticals Inc. has secured FDA approval for NELARABINE (ANDA216038), signaling the company's entry into the oncology market and initiating a comprehensive strategic review of coverage and market positioning for this intravenous chemotherapy agent. This new approval allows for the launch of a first-to-file product that is poised to compete against established brand formulations and biosimilars, potentially driving revenue opportunities in the rapidly expanding intravenous oncology therapeutic space.